Search

Objective: To evaluate the effectiveness of online group cognitive behavioral therapy (CBT) based on the CAMALEO TOC manual in the treatment of adolescents with obsessive-compulsive disorder (OCD)., Methods: This is a quasi-experimental study with a single-group pretest-posttest intervention. Over a 12-week period, 11 adolescents aged 11 to 17 years with OCD participated in weekly online group CBT sessions based on the CAMALEO TOC manual. We used several assessment tools, including the Children's Yale-Brown Obsessive-Compulsive Scale to assess the severity of OCD symptoms, the Family Accommodation Scale for Obsessive-Compulsive Disorder-Interviewer-Rated to measure family accommodation, the Children's Depression Inventory to assess depression symptoms, the Revised Children's Manifest Anxiety Scale to assess anxiety, and the Multidimensional Students' Life Satisfaction Scale to measure satisfaction with life., Results: OCD symptoms decreased significantly (d = -1.55) after online group CBT, and a strong effect size (d = -1.03) was found for family accommodation. After controlling for variables (e.g., engagement in psychotherapeutic treatment, medication use, or psychiatric comorbidities), no significant differences were found for OCD symptoms and family accommodation scores. In addition, there was insufficient evidence to support the effectiveness of online group CBT in reducing symptoms of depression or anxiety or improving overall quality of life., Conclusion: Our study demonstrates the feasibility of short-term online group CBT as an effective therapeutic approach for adolescents with OCD., Competing Interests: The authors report no conflicts of interest.

Objective: To evaluate the effectiveness of group cognitive-behavioral therapy (GCBT) for the treatment of adolescents with obsessive compulsive disorder (OCD)., Methods: This review was registered in PROSPERO under number CRD42020158475. Five databases (PubMed, Virtual Health Library, Web of Science, Scopus, and PsycINFO) were searched. After applying the inclusion and exclusion criteria, 13 studies were analyzed in the qualitative synthesis (i.e., systematic review) and eight in the quantitative synthesis (i.e., meta-analysis). For the latter, fixed-effect modeling was used to assess the primary outcome (i.e., OCD symptoms)., Results: The main findings suggest that GCBT is effective in reducing the symptoms of OCD in adolescents (d = -1.32). However, these results must be interpreted with caution, since all of the included studies showed some bias in their design., Conclusions: GCBT is effective in reducing OCD symptoms in adolescents., Competing Interests: The authors report no conflicts of interest.

Introduction: Suicide is a serious public health problem that affects the whole world. This study describes development of the prototype for an mHealth application (app) intended to assist healthcare professionals to identify suicide risk in hospitalized patients and reports on testing of the app by some of these professionals, conducted to confirm its functionality., Method: This is applied exploratory research into use of Information Technology within the healthcare field, based on application prototyping for mobile devices. The research was conducted at the Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA) from 2017 to 2019. Six healthcare professionals, one data scientist, and three undergraduate students in Biomedical Informatics took part in the study. All research participants signed the free and informed consent form., Results: The main findings show that the development team created a prototype named Detect-S, which became a cross-platform application (iOS and Android) offering 16 functions., Conclusion: It can be concluded that Detect-S has the potential to be a positive technological instrument that can be tested in a hospital setting to assist healthcare professionals to identify and manage patients with at risk of suicide., Competing Interests: All authors have a patent Detect-S, with royalties paid. Ygor Arzeno Ferrão has also received personal fees from Abbott, Lundbeck, GSK, and Pfizer. No other conflicts of interest declared concerning publication of this article.